← Back to Clinical Trials
Recruiting NCT04049591

NCT04049591 Higher vs. Lower Dose Heparin for PCI

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT04049591
Status Recruiting
Phase
Sponsor Population Health Research Institute
Condition Cardiovascular Diseases
Study Type INTERVENTIONAL
Enrollment 16,000 participants
Start Date 2022-03-02
Primary Completion 2024-10-08

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Higher Dose UFHLower Dose UFH

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 16,000 participants in total. It began in 2022-03-02 with a primary completion date of 2024-10-08.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

HD PCI is a multicenter, randomized, registry-based, cluster crossover design trial of higher dose versus lower dose heparin in patients undergoing elective percutaneous coronary intervention (PCI).

Eligibility Criteria

Inclusion Criteria: \- Patients undergoing elective PCI Exclusion Criteria: * Age \<18 years * Planned chronic total occlusion PCI * Non-resident precluding follow up through local registries Hospital (Cluster) Eligibility Criteria Hospitals will be eligible to participate if they meet the following criteria: * Submit PCI procedure data to a compatible registry that is able to provide data for the trial * Site agrees to manage patients as per the higher or lower dose heparin policy in place during the given crossover period

Contact & Investigator

Central Contact

Jessica Tyrwhitt

✉ HD-PCI@phri.ca

📞 905-521-2100

Principal Investigator

Sanjit Jolly, MD

PRINCIPAL INVESTIGATOR

Population Health Research Institute

Frequently Asked Questions

Who can join the NCT04049591 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Cardiovascular Diseases. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT04049591 currently recruiting?

Yes, NCT04049591 is actively recruiting participants. Contact the research team at HD-PCI@phri.ca for enrollment information.

Where is the NCT04049591 trial being conducted?

This trial is being conducted at Hamilton, Canada.

Who is sponsoring the NCT04049591 clinical trial?

NCT04049591 is sponsored by Population Health Research Institute. The principal investigator is Sanjit Jolly, MD at Population Health Research Institute. The trial plans to enroll 16,000 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology